Queen Mary University of London Leads Trial Showing Promise for Aggressive Lung Cancer

A clinical trial led by Queen Mary University of London leads to the significant increase in the survival of people with malignant mesothelioma, a rare, but rapidly fatal type of cancer with few effective treatment options.

Professor Peter Szlosarek at Queen Mary led the phase 3 clinical trial, sponsored by Polaris Pharmaceuticals. The study has unveiled a breakthrough in the treatment of malignant pleural mesothelioma (MPM), a rare and often rapidly fatal form of cancer with limited therapeutic options.